ICH Q3A Impurities in New Drug Substances
E555141
ICH Q3A Impurities in New Drug Substances is an international regulatory guideline that sets quality standards and thresholds for identifying, reporting, and controlling impurities in new active pharmaceutical ingredients.
All labels observed (1)
| Label | Occurrences |
|---|---|
| ICH Q3A Impurities in New Drug Substances canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T5932233 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: ICH Q3A Impurities in New Drug Substances Context triple: [ICH, notableGuideline, ICH Q3A Impurities in New Drug Substances]
-
A.
ICH Q8 Pharmaceutical Development
ICH Q8 Pharmaceutical Development is an international guideline that outlines a systematic, science- and risk-based approach to pharmaceutical product and process development, forming a core part of the ICH quality framework.
-
B.
ICH Q10 Pharmaceutical Quality System
ICH Q10 Pharmaceutical Quality System is an international guideline that establishes a comprehensive, lifecycle-based framework for pharmaceutical quality management to ensure consistent product quality and regulatory compliance.
-
C.
Certificates of Suitability to the monographs of the European Pharmacopoeia
Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
-
D.
ICH Q9 Quality Risk Management
ICH Q9 Quality Risk Management is an international guideline that provides a systematic, science- and risk-based approach to identifying, evaluating, and controlling quality risks throughout the lifecycle of pharmaceutical products.
-
E.
Office of Pharmaceutical Quality
The Office of Pharmaceutical Quality is a U.S. Food and Drug Administration office responsible for ensuring the quality, safety, and consistency of human drugs throughout their lifecycle.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: ICH Q3A Impurities in New Drug Substances Target entity description: ICH Q3A Impurities in New Drug Substances is an international regulatory guideline that sets quality standards and thresholds for identifying, reporting, and controlling impurities in new active pharmaceutical ingredients.
-
A.
ICH Q8 Pharmaceutical Development
ICH Q8 Pharmaceutical Development is an international guideline that outlines a systematic, science- and risk-based approach to pharmaceutical product and process development, forming a core part of the ICH quality framework.
-
B.
ICH Q10 Pharmaceutical Quality System
ICH Q10 Pharmaceutical Quality System is an international guideline that establishes a comprehensive, lifecycle-based framework for pharmaceutical quality management to ensure consistent product quality and regulatory compliance.
-
C.
Certificates of Suitability to the monographs of the European Pharmacopoeia
Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
-
D.
ICH Q9 Quality Risk Management
ICH Q9 Quality Risk Management is an international guideline that provides a systematic, science- and risk-based approach to identifying, evaluating, and controlling quality risks throughout the lifecycle of pharmaceutical products.
-
E.
Office of Pharmaceutical Quality
The Office of Pharmaceutical Quality is a U.S. Food and Drug Administration office responsible for ensuring the quality, safety, and consistency of human drugs throughout their lifecycle.
- F. None of above. chosen
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
ICH quality guideline
ⓘ
pharmaceutical regulatory guideline ⓘ |
| abbreviation | ICH Q3A NERFINISHED ⓘ |
| addresses |
batch analysis for impurity profiling
ⓘ
specification setting for impurities ⓘ stability studies with respect to impurities ⓘ |
| aimsTo |
avoid unnecessary differences in impurity requirements between regions
ⓘ
provide a consistent approach to impurity control in new drug substances ⓘ |
| appliesDuring |
drug development
ⓘ
marketing authorisation applications ⓘ |
| appliesTo |
new active pharmaceutical ingredients
ⓘ
new drug substances ⓘ |
| basisFor | regulatory assessment of impurity specifications in new drug substance dossiers ⓘ |
| concerns |
quality impact of impurities
ⓘ
safety impact of impurities ⓘ |
| covers |
inorganic impurities
ⓘ
organic impurities ⓘ residual solvents ⓘ |
| defines |
requirements for identification of impurities
ⓘ
requirements for qualification of impurities ⓘ requirements for reporting of impurities ⓘ thresholds for identification of impurities ⓘ thresholds for qualification of impurities ⓘ thresholds for reporting of impurities ⓘ |
| documentType | scientific and technical guideline ⓘ |
| excludes | biotechnological and biological products ⓘ |
| focusesOn | impurities in new drug substances ⓘ |
| issuedBy | International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use NERFINISHED ⓘ |
| language | English ⓘ |
| objective |
to ensure safety and quality of new active pharmaceutical ingredients
ⓘ
to harmonise impurity control requirements for new drug substances among ICH regions ⓘ |
| region |
European Union
NERFINISHED
ⓘ
Japan NERFINISHED ⓘ United States of America ⓘ
surface form:
United States
|
| regulatoryDomain |
drug substance quality
ⓘ
pharmaceutical quality ⓘ |
| relatedGuideline |
ICH Q3B Impurities in New Drug Products
NERFINISHED
ⓘ
ICH Q3C Impurities: Guideline for Residual Solvents NERFINISHED ⓘ |
| requires |
appropriate analytical procedures for impurity detection
ⓘ
justification of impurity limits ⓘ safety qualification of significant impurities ⓘ |
| targetAudience |
analytical chemists in pharmaceutical development
ⓘ
quality assurance professionals ⓘ regulatory affairs professionals ⓘ |
| usedBy |
pharmaceutical industry
ⓘ
regulatory authorities in ICH regions ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: ICH Q3A Impurities in New Drug Substances Description of subject: ICH Q3A Impurities in New Drug Substances is an international regulatory guideline that sets quality standards and thresholds for identifying, reporting, and controlling impurities in new active pharmaceutical ingredients.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.